Literature DB >> 16034366

Id family of helix-loop-helix proteins in cancer.

Jonathan Perk1, Antonio Iavarone, Robert Benezra.   

Abstract

Over the past few decades, biologists have identified key molecular signatures associated with a wide range of human cancers. Recently, animal models have been particularly useful in establishing whether such signatures have functional relevance; the overexpression of pro-oncogenic or loss of anti-oncogenic factors have been evaluated for their effects on various tumour models. The aim of this review is to analyze the potential role of the inhibitor of DNA binding (Id) proteins in cancer and examine whether deregulated Id activity is tumorigenic and contributes to hallmarks of malignancy, such as loss of differentiation (anaplasia), unrestricted proliferation and neoangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034366     DOI: 10.1038/nrc1673

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  228 in total

1.  Smurf2-mediated ubiquitination and degradation of Id1 regulates p16 expression during senescence.

Authors:  Yahui Kong; Hang Cui; Hong Zhang
Journal:  Aging Cell       Date:  2011-10-07       Impact factor: 9.304

Review 2.  Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Rik Derynck
Journal:  Cells Tissues Organs       Date:  2010-11-02       Impact factor: 2.481

Review 3.  APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity.

Authors:  Xinxian Qiao; Liyong Zhang; Armin M Gamper; Takeo Fujita; Yong Wan
Journal:  Cell Cycle       Date:  2010-10-11       Impact factor: 4.534

4.  Physical and functional interaction between the ID1 and p65 for activation of NF-κB.

Authors:  Xiao Peng; Yuna Wang; Swapna Kolli; Junpeng Deng; Li Li; Zhixin Wang; J Usha Raj; Deming Gou
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-16       Impact factor: 4.249

5.  ID4 regulates mammary gland development by suppressing p38MAPK activity.

Authors:  Jie Dong; Shixia Huang; Marian Caikovski; Shaoquan Ji; Amanda McGrath; Myra G Custorio; Chad J Creighton; Paul Maliakkal; Ekaterina Bogoslovskaia; Zhijun Du; Xiaomei Zhang; Michael T Lewis; Fred Sablitzky; Cathrin Brisken; Yi Li
Journal:  Development       Date:  2011-12       Impact factor: 6.868

Review 6.  New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Authors:  Giada Zurlo; Jianping Guo; Mamoru Takada; Wenyi Wei; Qing Zhang
Journal:  Biochim Biophys Acta       Date:  2016-09-20

7.  Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.

Authors:  Binwu Tang; Naomi Yoo; Mary Vu; Mizuko Mamura; Jeong-Seok Nam; Akira Ooshima; Zhijun Du; Pierre-Yves Desprez; Miriam R Anver; Aleksandra M Michalowska; Joanna Shih; W Tony Parks; Lalage M Wakefield
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  MyoD is a tumor suppressor gene in medulloblastoma.

Authors:  Joyoti Dey; Adrian M Dubuc; Kyle D Pedro; Derek Thirstrup; Brig Mecham; Paul A Northcott; Xiaochong Wu; David Shih; Stephen J Tapscott; Michael LeBlanc; Michael D Taylor; James M Olson
Journal:  Cancer Res       Date:  2013-10-03       Impact factor: 12.701

9.  Active gene repression by the Egr2.NAB complex during peripheral nerve myelination.

Authors:  Gennifer M Mager; Rebecca M Ward; Rajini Srinivasan; Sung-Wook Jang; Lawrence Wrabetz; John Svaren
Journal:  J Biol Chem       Date:  2008-05-02       Impact factor: 5.157

10.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.